Printer Friendly

PET for cancer staging. (Policy & Practice).

Starting Oct. 1, Medicare will cover positron emission tomography scans using [fluorodeoxyglucose.sup.18] (FD G-PET) for staging breast cancer and for restaging locoregional recurrence or metastasis. Fluorodeoxyglucose is a radioactive tracer substance that is drawn to high levels of metabolic activity, as in a tumor. The Centers for Medicare and Medicaid Services announced the coverage decision in a May 2 program memorandum. Medicaid still does not cover PET for initial diagnosis of breast cancer or for initial staging of axillary lymph nodes.
COPYRIGHT 2002 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Peters, Sally
Publication:OB GYN News
Date:Jun 15, 2002
Previous Article:Contak CD CRT-D System. (New & Approved).
Next Article:Women's health survey. (Policy & Practice).

Related Articles
CTI, Inc., Reports HCFA to Provide Expanded Medicare Coverage for Positron Emission Tomography (PET).
Major Breakthrough for Women With Diagnosis of Breast Cancer.
Limitations emerge for FDG-PET in oncology. (Clinical Rounds: Confounding physiologic effects of tracer).
New Research Shows PET Should Be Used For Evaluation of Gleevec(TM) Response in GIST.
Cancer Centers of Florida Utilizes Mobile PET System to Improve Detection, Treatment of Cancer.
PET Imaging Leader CTI Comments on Medicare Announcement of Broad Coverage for All Cancers.
US Oncology Expands PET Network With New Systems in Texas and Illinois.
CMS will expand coverage for initial PET scans.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters